<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dermatophyte (tinea) infections</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dermatophyte (tinea) infections</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Dermatophyte (tinea) infections</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam O Goldstein, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beth G Goldstein, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ted Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Dermatophyte infections are common worldwide, and dermatophytes are the prevailing causes of fungal infection of the skin, hair, and nails [<a href="#rid1">1-3</a>]. These infections lead to a variety of clinical manifestations, such as tinea pedis  (<a class="graphic graphic_picture graphicRef76067 graphicRef103981 graphicRef82787" href="/d/graphic/76067.html" rel="external">picture 1A-C</a>), tinea corporis  (<a class="graphic graphic_picture graphicRef129803 graphicRef103984 graphicRef99892 graphicRef75928" href="/d/graphic/129803.html" rel="external">picture 2A-D</a>), tinea cruris  (<a class="graphic graphic_picture graphicRef71067 graphicRef129944 graphicRef129802 graphicRef117699 graphicRef76169" href="/d/graphic/71067.html" rel="external">picture 3A-E</a>), tinea capitis  (<a class="graphic graphic_picture graphicRef101858 graphicRef86686" href="/d/graphic/101858.html" rel="external">picture 4A-B</a>), dermatophyte onychomycosis (tinea unguium  (<a class="graphic graphic_picture graphicRef120659" href="/d/graphic/120659.html" rel="external">picture 5</a>)), and Majocchi's granuloma  (<a class="graphic graphic_picture graphicRef103536 graphicRef129800 graphicRef103535" href="/d/graphic/103536.html" rel="external">picture 6A-C</a>).</p><p>The clinical features, diagnosis, and management of dermatophyte infections of the skin will be reviewed here  (<a class="graphic graphic_algorithm graphicRef131608" href="/d/graphic/131608.html" rel="external">algorithm 1</a>). Dermatophyte infections of scalp hair (tinea capitis), beard hair (tinea barbae), and nails (tinea unguium or dermatophyte onychomycosis) are discussed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/99983.html" rel="external">"Tinea capitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Dermatophytic folliculitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4034.html" rel="external">"Onychomycosis: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/105222.html" rel="external">"Onychomycosis: Management"</a>.)</p><p></p><p>The term "tinea" is also used in the names of some cutaneous fungal infections that are not caused by dermatophytes. These disorders are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4039.html" rel="external">"Tinea versicolor (pityriasis versicolor)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/110106.html" rel="external">"Tinea nigra"</a>.)</p><p></p><p class="headingAnchor" id="H2672358738"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>Dermatophytes are filamentous fungi in the genera <em>Trichophyton</em>, <em>Microsporum</em>,<em> </em>and <em>Epidermophyton</em>. Dermatophytes metabolize and subsist upon keratin in the skin, hair, and nails.</p><p class="headingAnchor" id="H1185950683"><span class="h1">CLINICAL SUBTYPES</span><span class="headingEndMark"> — </span>The major clinical subtypes of dermatophyte infections include infections of the epidermis, hair, and nails.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidermis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tinea corporis </strong>– Infection of body surfaces other than the feet, groin, face, scalp hair, or beard hair</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tinea pedis </strong>– Infection of the foot</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tinea cruris </strong>– Infection of the groin, proximal inner thighs, or buttocks</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tinea faciei</strong> – Infection of the face</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tinea manuum</strong> – Infection of the hand</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hair</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tinea capitis </strong>– Infection of scalp hair</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tinea barbae</strong> – Infection of beard hair </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nails</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dermatophyte onychomycosis (tinea unguium) </strong></p><p></p><p>Majocchi's granuloma is an additional subtype of dermatophyte infection characterized by the spread of epidermal infection into deep portions of the hair follicle and dermis. (See  <a class="medical medical_review" href="/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Dermatophytic folliculitis'</a>.)</p><p class="headingAnchor" id="H1219713189"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Cutaneous dermatophyte infections may be strongly suspected based upon the physical examination. However, because the physical findings can overlap with other cutaneous disorders, we typically confirm the diagnosis with testing.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – A careful physical examination of the affected areas allows for recognition of findings consistent with or inconsistent with the suspected dermatophyte infection. (See <a class="local">'Tinea pedis'</a> below and <a class="local">'Tinea corporis'</a> below and <a class="local">'Tinea cruris'</a> below and <a class="local">'Other clinical variants'</a> below.)</p><p></p><p class="bulletIndent1">Because the simultaneous presence of more than one type of dermatophyte infection is not uncommon (eg, tinea pedis and tinea cruris or tinea pedis and tinea unguium), performance of a full skin examination including the skin, hair, and nails aids in the detection of additional sites of infection. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic tests</strong> – The approach to diagnostic testing differs based upon the suspected type of infection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Epidermal infections (eg, tinea pedis, tinea corporis, tinea cruris)</strong> – A potassium hydroxide (KOH) preparation performed with skin scrapings from the affected areas is the primary method of confirming dermatophyte infections of the epidermis (eg, tinea corporis, tinea pedis, tinea cruris, tinea manuum, tinea faciei)  (<a class="graphic graphic_algorithm graphicRef131608" href="/d/graphic/131608.html" rel="external">algorithm 1</a>). A major advantage of the KOH preparation is the rapid availability of results, as the test can be performed by the evaluating clinician. Fungal culture is an alternative, albeit slower, method for diagnosis. (See  <a class="medical medical_review" href="/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Potassium hydroxide preparation'</a> and  <a class="medical medical_review" href="/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Fungal culture'</a>.)</p><p></p><p class="bulletIndent2">The detection of segmented hyphae on a KOH preparation confirms a dermatophyte infection  (<a class="graphic graphic_picture graphicRef100246 graphicRef60102" href="/d/graphic/100246.html" rel="external">picture 7A-B</a>). This finding should be distinguished from the findings of budding yeasts, pseudohyphae, and septate hyphae on a KOH preparation from <em>Candida</em> infection  (<a class="graphic graphic_picture graphicRef51081 graphicRef64872" href="/d/graphic/51081.html" rel="external">picture 8A-B</a>) and the short hyphae and yeast cells found in a KOH preparation from tinea versicolor  (<a class="graphic graphic_picture graphicRef58965" href="/d/graphic/58965.html" rel="external">picture 9</a>). Clinician experience and proper technique influence the diagnostic accuracy of a KOH preparation [<a href="#rid4">4</a>]. The technique for performing a KOH preparation is reviewed separately. (See  <a class="medical medical_review" href="/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Potassium hydroxide preparation'</a>.)</p><p></p><p class="bulletIndent2">Collection of an adequate specimen for a KOH preparation or fungal culture is important. In patients with tinea corporis or tinea cruris, the highest yield may be obtained from skin scrapings taken from the active border of a plaque or patch. In vesicobullous tinea pedis, the roof of a vesicle can provide an adequate specimen.</p><p></p><p class="bulletIndent2">Polymerase chain reaction (PCR) tests have an emerging role in the diagnosis of dermatophytoses. (See  <a class="medical medical_review" href="/d/html/4034.html" rel="external">"Onychomycosis: Epidemiology, clinical features, and diagnosis", section on 'Polymerase chain reaction'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hair or nail infections</strong> – The approach to the diagnosis of infections of the hair or nails is reviewed separately.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/d/html/99983.html" rel="external">"Tinea capitis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/d/html/4034.html" rel="external">"Onychomycosis: Epidemiology, clinical features, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H2379729560"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Potential complications of dermatophyte infection include secondary bacterial infection, tinea incognito, Majocchi's granuloma, and id reactions.</p><p class="headingAnchor" id="H4092784445"><span class="h2">Secondary infection</span><span class="headingEndMark"> — </span>Secondary bacterial infection can occur in association with dermatophyte infections, particularly in moist or occluded skin areas (eg, the feet) [<a href="#rid5">5</a>]. Patients who exhibit significant erosions, ulceration, pain, or malodor in the affected area should have a Gram stain and culture to evaluate for secondary bacterial infection. (See <a class="local">'Tinea pedis'</a> below.)</p><p class="headingAnchor" id="H1537389341"><span class="h2">Tinea incognito and Majocchi's granuloma</span><span class="headingEndMark"> — </span>Misdiagnosis of a dermatophyte infection as a corticosteroid-responsive dermatosis (eg, eczema) may result in the inadvertent use of topical corticosteroids for treatment. The local immunosuppressive effects of topical corticosteroids can exacerbate dermatophyte infections and alter the clinical findings, making diagnosis more difficult (ie, tinea incognito) [<a href="#rid6">6</a>]. Alterations to the clinical presentation may include diminished erythema and scale or loss of a well-defined border.</p><p>Although the term "tinea incognito" is extensively used in the literature, it is grammatically incorrect according to Latin grammar rules [<a href="#rid7">7,8</a>]. The grammatically correct term, "tinea incognita," is also used.</p><p>In addition, topical corticosteroid use may promote extension of the infection into the hair follicle and dermis, resulting in Majocchi's granuloma, which requires oral antifungal treatment [<a href="#rid9">9</a>]. Similarly, in immunosuppressed patients, the depression of cell-mediated immunity and the inflammatory response may contribute to progression of epidermal dermatophyte infections to Majocchi's granuloma [<a href="#rid10">10-13</a>]. (See  <a class="medical medical_review" href="/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Dermatophytic folliculitis'</a>.)</p><p class="headingAnchor" id="H120428435"><span class="h2">Id reactions</span><span class="headingEndMark"> — </span>Autoeczematization reactions (also known as id reactions) are secondary, dermatitic eruptions that occur in association with primary, often inflammatory, skin disorders. The term "dermatophytid reaction" describes this occurrence in relation to a dermatophyte infection. The pathogenesis may involve an immunologic reaction to fungal antigens similar to a delayed-type hypersensitivity response [<a href="#rid14">14</a>].</p><p>Dermatophytid reactions can occur in patients with tinea pedis, tinea manuum, tinea cruris, tinea corporis, or tinea capitis [<a href="#rid14">14-16</a>]. Patients typically present with pruritic, papulovesicular eruptions that can be quite distant from the site of infection  (<a class="graphic graphic_picture graphicRef52664 graphicRef63421" href="/d/graphic/52664.html" rel="external">picture 10A-B</a>). </p><p>In one series of 213 patients with tinea pedis, 37 patients (17 percent) were diagnosed with dermatophytid reactions characterized by vesicular eruptions on the hands [<a href="#rid17">17</a>]. A separate series of five children with dermatophytid reactions due to tinea capitis found that in addition to involvement on the head and neck, trunk and extremity lesions were common [<a href="#rid14">14</a>].</p><p>The management of dermatophytid reactions involves the successful treatment of the dermatophyte infection; this may be compromised if the reaction is mistaken for a drug eruption related to antifungal therapy. Topical corticosteroids and antipruritic agents are typically used for acute management. Rarely, systemic glucocorticoids are needed.</p><p class="headingAnchor" id="H435103099"><span class="h1">TREATMENT PRINCIPLES</span><span class="headingEndMark"> — </span>Treatment of dermatophyte infections is generally indicated. Treatment is given to alleviate symptoms (eg, pruritus), reduce risk for secondary bacterial infection, and limit spread of the infection to other body sites or other individuals. </p><p class="headingAnchor" id="H1217398057"><span class="h2">Treatment options</span><span class="headingEndMark"> — </span>Treatment consists of topical or systemic antifungal drugs with antidermatophyte activity  (<a class="graphic graphic_algorithm graphicRef131608" href="/d/graphic/131608.html" rel="external">algorithm 1</a>).</p><p>Most cutaneous dermatophyte infections limited to the epidermis can be managed with topical antifungal therapy. Examples of agents effective for dermatophyte infections include azoles, allylamines, <a class="drug drug_general" data-topicid="9177" href="/d/drug information/9177.html" rel="external">butenafine</a>, <a class="drug drug_general" data-topicid="9263" href="/d/drug information/9263.html" rel="external">ciclopirox</a>, and <a class="drug drug_general" data-topicid="10005" href="/d/drug information/10005.html" rel="external">tolnaftate</a>  (<a class="graphic graphic_table graphicRef76148" href="/d/graphic/76148.html" rel="external">table 1</a>). </p><p>Oral treatment with agents such as <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a>, <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, and <a class="drug drug_general" data-topicid="8502" href="/d/drug information/8502.html" rel="external">griseofulvin</a> is used for extensive infections, infections that are refractory to topical therapy, or infections extending into follicles or the dermis (eg, tinea capitis, tinea barbae, Majocchi's granuloma) or involving nails. Oral therapy is typically reserved for these presentations because of the broader side effect profile compared with topical therapy. Cutaneous adverse reactions, hepatotoxicity, and drug interactions are among the potential complications of oral antifungal therapy. (See  <a class="drug drug_general" href="/d/drug information/9922.html" rel="external">"Terbinafine (systemic): Drug information"</a> and  <a class="drug drug_general" href="/d/drug information/8586.html" rel="external">"Itraconazole: Drug information"</a> and  <a class="drug drug_general" href="/d/drug information/8450.html" rel="external">"Fluconazole: Drug information"</a> and  <a class="drug drug_general" href="/d/drug information/8502.html" rel="external">"Griseofulvin: Drug information"</a>.)</p><p>Use of oral <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> is no longer recommended because of risk for severe liver injury, adrenal insufficiency, and drug interactions. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Ketoconazole'</a>.)</p><p class="headingAnchor" id="H337961859"><span class="h2">Nystatin ineffective</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9712" href="/d/drug information/9712.html" rel="external">Nystatin</a>, an effective treatment for cutaneous <em>Candida</em> infections, is <strong>not</strong> effective for dermatophyte infections.</p><p class="headingAnchor" id="H936872439"><span class="h2">Adjunctive corticosteroid therapy</span><span class="headingEndMark"> — </span>In general, we do <strong>not</strong> use topical corticosteroids in the treatment of dermatophyte infections. Although combination antifungal and low-potency corticosteroid products can be effective and may accelerate resolution of the clinical manifestations of superficial dermatophyte infections [<a href="#rid18">18</a>], combination therapy is not necessary for achieving cure. In particular, use of products that include medium- or high-potency corticosteroids (eg, <a class="drug drug_general" data-topicid="8655" href="/d/drug information/8655.html" rel="external">betamethasone-clotrimazole</a>) is discouraged because use of a topical corticosteroid introduces risk for topical corticosteroid-induced skin atrophy. Treatment failures have also been reported [<a href="#rid19">19-21</a>], and some authors postulate that overuse of topical corticosteroids may contribute to the emergence of resistant dermatophyte infections. (See <a class="local">'Treatment failure'</a> below.)</p><p>An <strong>infrequent</strong> exception to our avoidance of combination therapy is the addition of a <strong>low-potency</strong> topical corticosteroid (group 6 or 7) to antifungal therapy for patients with highly inflammatory lesions associated with severe pruritus  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 2</a>). Some topical antifungal drugs (eg, allylamines and <a class="drug drug_general" data-topicid="9263" href="/d/drug information/9263.html" rel="external">ciclopirox</a>) have intrinsic anti-inflammatory properties that may also help to reduce inflammation [<a href="#rid22">22,23</a>].</p><p class="headingAnchor" id="H3513546652"><span class="h2">Treatment failure</span><span class="headingEndMark"> — </span>Dermatophyte infections usually respond well to a course of appropriate treatment.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient assessment</strong> – Common reasons for failure to respond to antifungal therapy include inadequate administration of treatment (eg, stopping treatment as visible scale resolves) or an incorrect diagnosis  (<a class="graphic graphic_algorithm graphicRef131608" href="/d/graphic/131608.html" rel="external">algorithm 1</a>). Therefore, an evaluation of apparent treatment failure should include discussion of the use of the prescribed therapy and consideration of alternative diagnoses. The possibility of reinfection should also be reviewed.</p><p></p><p class="bulletIndent1">Immunosuppression may increase risk for dermatophyte infection and may contribute to the development of extensive or persistent disease. The possibility of an underlying immune disorder should be considered in patients with particularly severe, treatment-refractory disease. (See  <a class="medical medical_review" href="/d/html/3741.html" rel="external">"Initial evaluation of adults with HIV", section on 'Physical examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifungal resistance</strong> – Emerging resistance of dermatophyte infections to antifungal therapy may account for some treatment failures. <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">Terbinafine</a> resistance secondary to single point mutations in the squalene oxidase gene has been reported most frequently [<a href="#rid24">24</a>]. Examples of other proposed mechanisms for resistance to antifungal therapies include upregulation of efflux pumps and mutations in the lanosterol-14-alpha demethylase gene [<a href="#rid24">24</a>]. Although not routinely performed in many locations, susceptibility testing may be of value for patients with confirmed dermatophyte infections that fail to respond to appropriate course of treatment [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>Trichophyton indotineae</em></strong> – <em>Trichophyton indotineae</em> is a highly transmissible species of dermatophyte that is often associated with resistance to antifungal therapy, particularly <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> [<a href="#rid25">25,26</a>]. Infections have been reported in Asia, Europe, North America, and the Middle East [<a href="#rid27">27</a>]. Infections most often present as annular, inflamed, scaly plaques on multiple body areas (tinea corporis, tinea cruris, and/or tinea faciei) [<a href="#rid25">25,27</a>].</p><p></p><p class="bulletIndent2"><em>T. indotineae</em> cannot be identified through routine laboratory techniques due to morphologic similarities among <em>T. indotineae</em>, <em>Trichophyton mentagrophytes</em>, and<em> Trichophyton interdigitale</em>. Genomic sequencing is required for identification. Misuse and overuse of topical antifungal drugs and topical corticosteroids are proposed to contribute to the spread of resistant <em>T. indotineae </em>infections [<a href="#rid25">25,26</a>].</p><p></p><p class="headingAnchor" id="H15"><span class="h1">TINEA PEDIS</span></p><p class="headingAnchor" id="H2658711829"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Tinea pedis (also known as athlete's foot) is a dermatophyte infection of the skin on the foot.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology and risk factors</strong> – Tinea pedis usually occurs in adults and adolescents and is rare prior to puberty [<a href="#rid28">28</a>]. Common causes are <em>Trichophyton rubrum</em>, <em>T. mentagrophytes</em>/<em>interdigitale</em> complex, and <em>Epidermophyton floccosum</em>.</p><p></p><p class="bulletIndent1">Infection is usually acquired by means of direct contact with the causative organism, as may occur by walking barefoot in locker rooms or swimming pool facilities. Other predisposing factors may include diabetes mellitus and the wearing of occlusive footwear [<a href="#rid29">29-31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Tinea pedis may manifest in a variety of ways. The three major clinical types of tinea pedis are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Interdigital tinea pedis </strong>– Interdigital tinea pedis manifests as pruritic erosions or scales between the toes, especially in the third and fourth digital interspaces  (<a class="graphic graphic_picture graphicRef76067" href="/d/graphic/76067.html" rel="external">picture 1A</a>). Associated interdigital fissures may cause pain.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hyperkeratotic (moccasin-type) tinea pedis </strong>– Hyperkeratotic tinea pedis is characterized by a diffuse, hyperkeratotic eruption involving the soles and medial and lateral surfaces of the feet, resembling a "moccasin" distribution  (<a class="graphic graphic_picture graphicRef103981" href="/d/graphic/103981.html" rel="external">picture 1B</a>). There is a variable degree of underlying erythema.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vesiculobullous (inflammatory) tinea pedis </strong>– Vesiculobullous tinea pedis is characterized by a pruritic, sometimes painful, vesicular or bullous eruption  (<a class="graphic graphic_picture graphicRef129203 graphicRef82787" href="/d/graphic/129203.html" rel="external">picture 1C-D</a>). Underlying erythema may be evident. The medial foot is often affected.</p><p></p><p class="bulletIndent1">Infrequently, tinea pedis may manifest with interdigital erosions and ulcers (<strong>ulcerative tinea pedis</strong>)  (<a class="graphic graphic_picture graphicRef103978 graphicRef103979" href="/d/graphic/103978.html" rel="external">picture 11A-B</a>). This presentation is usually associated with secondary bacterial infection.</p><p></p><p class="bulletIndent1">Tinea pedis can occur in association with onychomycosis, tinea cruris, or tinea manuum  (<a class="graphic graphic_picture graphicRef129202" href="/d/graphic/129202.html" rel="external">picture 12A</a>).</p><p></p><p class="headingAnchor" id="H300476"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of tinea pedis is broad and varies according to the clinical subtype.</p><p class="bulletIndent1"><span class="glyph">●</span>Interdigital tinea pedis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Erythrasma  (<a class="graphic graphic_picture graphicRef99903" href="/d/graphic/99903.html" rel="external">picture 13</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Interdigital <em>Candida</em> infection (erosio interdigitalis blastomycetica  (<a class="graphic graphic_picture graphicRef79187" href="/d/graphic/79187.html" rel="external">picture 14</a>))</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperkeratotic (moccasin-type) tinea pedis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Atopic dermatitis</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic contact dermatitis  (<a class="graphic graphic_picture graphicRef51220" href="/d/graphic/51220.html" rel="external">picture 15</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic palmoplantar (dyshidrotic) eczema  (<a class="graphic graphic_picture graphicRef82782" href="/d/graphic/82782.html" rel="external">picture 16</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Palmoplantar psoriasis  (<a class="graphic graphic_picture graphicRef99481" href="/d/graphic/99481.html" rel="external">picture 17</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Pitted keratolysis  (<a class="graphic graphic_picture graphicRef81393" href="/d/graphic/81393.html" rel="external">picture 18</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Juvenile plantar dermatosis  (<a class="graphic graphic_picture graphicRef62551 graphicRef76443" href="/d/graphic/62551.html" rel="external">picture 19A-B</a>) (see  <a class="medical medical_review" href="/d/html/1727.html" rel="external">"Overview of dermatitis (eczematous dermatoses)", section on 'Juvenile plantar dermatosis'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Keratolysis exfoliativa  (<a class="graphic graphic_picture graphicRef126509" href="/d/graphic/126509.html" rel="external">picture 20</a>) (see  <a class="medical medical_review" href="/d/html/15512.html" rel="external">"Peeling skin syndromes", section on 'Keratolysis exfoliativa'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Keratodermas (see  <a class="medical medical_review" href="/d/html/110147.html" rel="external">"Palmoplantar keratoderma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vesiculobullous (inflammatory) tinea pedis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute palmoplantar (dyshidrotic) eczema  (<a class="graphic graphic_picture graphicRef103983" href="/d/graphic/103983.html" rel="external">picture 21</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Acute contact dermatitis</p><p class="bulletIndent2"><span class="glyph">•</span>Palmoplantar pustulosis  (<a class="graphic graphic_picture graphicRef98978" href="/d/graphic/98978.html" rel="external">picture 22</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Scabies  (<a class="graphic graphic_picture graphicRef56862" href="/d/graphic/56862.html" rel="external">picture 23</a>)</p><p></p><p>A positive potassium hydroxide (KOH) preparation demonstrating segmented hyphae distinguishes tinea pedis from nonfungal diseases. Interdigital <em>Candida</em> infection will demonstrate budding yeasts, pseudohyphae, and septate hyphae on a KOH preparation  (<a class="graphic graphic_picture graphicRef51081 graphicRef64872" href="/d/graphic/51081.html" rel="external">picture 8A-B</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p class="headingAnchor" id="H300483"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Topical antifungal therapy is the treatment of choice for most patients. Systemic antifungal agents are primarily reserved for patients who fail topical therapy  (<a class="graphic graphic_algorithm graphicRef131608" href="/d/graphic/131608.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong> – Examples of topical drugs effective for tinea pedis include azoles, allylamines, <a class="drug drug_general" data-topicid="9177" href="/d/drug information/9177.html" rel="external">butenafine</a>, <a class="drug drug_general" data-topicid="9263" href="/d/drug information/9263.html" rel="external">ciclopirox</a>, <a class="drug drug_general" data-topicid="10005" href="/d/drug information/10005.html" rel="external">tolnaftate</a>, and amorolfine  (<a class="graphic graphic_table graphicRef76148" href="/d/graphic/76148.html" rel="external">table 1</a>). Topical <a class="drug drug_general" data-topicid="9712" href="/d/drug information/9712.html" rel="external">nystatin</a> is <strong>not</strong> effective for dermatophyte infections. Amorolfine is not available in the United States. (See <a class="local">'Treatment principles'</a> above.)</p><p></p><p class="bulletIndent1">Topical antifungal treatment is generally applied once or twice daily and continued for four weeks. Shorter treatment courses may be effective; high cure rates have been obtained with <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> 1% cream applied to interdigital tinea pedis for one week [<a href="#rid32">32</a>]. </p><p></p><p class="bulletIndent1">A meta-analysis of randomized trials published prior to February 2005 supports efficacy of topical therapy, finding strong evidence of superiority of topical antifungal agents (azoles, allylamines, <a class="drug drug_general" data-topicid="9263" href="/d/drug information/9263.html" rel="external">ciclopirox</a>, <a class="drug drug_general" data-topicid="10005" href="/d/drug information/10005.html" rel="external">tolnaftate</a>, <a class="drug drug_general" data-topicid="9177" href="/d/drug information/9177.html" rel="external">butenafine</a>, and undecanoate) over placebo [<a href="#rid33">33</a>]. Allylamines may be slightly more effective than azoles. A meta-analysis of data from 11 trials that compared topical allylamines with topical azoles found slightly higher cure rates with allylamines (risk ratio of treatment failure 0.63, 95% CI 0.42-0.94) [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory disease</strong> – Patients with confirmed tinea pedis who fail topical therapy may be treated with an oral antifungal drug. Potential causes of treatment failure should be reviewed. (See <a class="local">'Treatment failure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adult dosing</strong> – Adults are usually treated with <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a>, <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, or <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>. Typical treatment regimens for adults are provide in a table  (<a class="graphic graphic_table graphicRef142692" href="/d/graphic/142692.html" rel="external">table 3</a>) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="8502" href="/d/drug information/8502.html" rel="external">Griseofulvin</a>, an oral antifungal agent frequently used for tinea capitis in children, can also treat tinea pedis but requires a longer duration of daily therapy [<a href="#rid34">34</a>]. Typical adult doses of griseofulvin are listed in a table  (<a class="graphic graphic_table graphicRef142692" href="/d/graphic/142692.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent2">Patient comorbidities, risk for drug interactions, and regimen preference influence the selection of an oral antifungal therapy. Differences in efficacy among most of the oral antifungal drugs used for tinea pedis have not been identified; however, many trials may have been underpowered to detect such differences [<a href="#rid35">35,36</a>]. Findings from a systematic review that identified two small, randomized trials that compared <a class="drug drug_general" data-topicid="8502" href="/d/drug information/8502.html" rel="external">griseofulvin</a> with <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> suggest greater efficacy of four- or six-week courses of terbinafine 250 mg per day compared with four- or six-week courses of griseofulvin 500 mg per day (risk ratio 2.26, 95% CI 1.49-3.44) [<a href="#rid35">35</a>]. However, these small trials assessed a longer duration of terbinafine treatment and a lower dose of griseofulvin than is often used for tinea pedis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pediatric dosing</strong> – Dosing for children is weight based, with similar durations of treatment compared with adults. Typical pediatric doses are provided in a table  (<a class="graphic graphic_table graphicRef142692" href="/d/graphic/142692.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive therapy</strong> <strong>for scale and maceration</strong> – In our experience, patients with hyperkeratotic tinea pedis may benefit from combining antifungal treatment with a topical keratolytic agent, such as salicylic acid, to accelerate resolution of scale. However, the addition of a keratolytic agent is not necessary for successful treatment of the infection.</p><p></p><p class="bulletIndent1">Patients with significant vesiculation or maceration may benefit from Burow solution (at a dose of 1% <a class="drug drug_general" data-topicid="95641" href="/d/drug information/95641.html" rel="external">aluminum acetate</a> or 5% aluminum subacetate) wet dressings to reduce moisture and maceration. The wet dressings can be applied for 20 minutes two to three times per day. Placing gauze or cotton between toes may also be helpful.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Interventions that may help to reduce recurrences include use of socks with wick-away material, use of desiccating foot powders, treatment of hyperhidrosis if there is a history of moist feet, treatment of shoes with antifungal powder, and avoidance of occlusive footwear.</p><p></p><p class="headingAnchor" id="H23"><span class="h1">TINEA CORPORIS</span></p><p class="headingAnchor" id="H1193420999"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The term "tinea corporis" refers to epidermal dermatophyte infections in sites other than the feet, groin, face, or hand.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology and risk factors</strong> – <em>T. rubrum</em> is the most common cause of tinea corporis. Other notable causes include <em>Trichophyton tonsurans</em>, <em>Microsporum canis</em>, <em>T. mentagrophytes</em>/<em>interdigitale</em> complex, <em>T. indotineae</em>, <em>Microsporum gypseum</em>, <em>Trichophyton violaceum</em>, and <em>Microsporum audouinii</em>.</p><p></p><p class="bulletIndent1">Acquisition of infection may occur by direct skin contact with an infected individual or animal, contact with fomites, or from secondary spread from other sites of dermatophyte infection (eg, scalp, feet, etc). In particular, <em>T. tonsurans </em>tinea corporis in adults may result from contact with a child with tinea capitis, which is often caused by this organism. <em>M. canis</em> tinea corporis is often acquired by contact with an infected cat or dog.</p><p></p><p class="bulletIndent1">Tinea corporis can also occur in outbreaks among athletes who have skin-to-skin contact, such as wrestlers (tinea corporis gladiatorum). <em>T. tonsurans</em> is a common cause of tinea corporis gladiatorum [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Tinea corporis often begins as a pruritic, circular or oval, erythematous or hyperpigmented, scaling patch or plaque that spreads centrifugally. Central clearing follows, while an active, advancing, raised border remains. The result is an annular (ring-shaped) plaque from which the disease derives its common name (ringworm  (<a class="graphic graphic_picture graphicRef129803 graphicRef103984 graphicRef99892 graphicRef75928" href="/d/graphic/129803.html" rel="external">picture 2A-D</a>)). Multiple plaques may coalesce  (<a class="graphic graphic_picture graphicRef55949 graphicRef53823" href="/d/graphic/55949.html" rel="external">picture 24A-B</a>). Pustules occasionally appear  (<a class="graphic graphic_picture graphicRef93727" href="/d/graphic/93727.html" rel="external">picture 25</a>).</p><p></p><p class="bulletIndent1">Extensive tinea corporis should prompt consideration of an underlying immune disorder, such as HIV, or for diabetes.</p><p></p><p class="headingAnchor" id="H68628070"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Examples of features that should prompt consideration of alternative diagnoses include extensive skin involvement and an absence of scale. A positive potassium hydroxide (KOH) preparation distinguishes tinea corporis.</p><p>Tinea corporis may be confused with other annular skin eruptions, particularly subacute cutaneous lupus erythematosus, granuloma annulare, and erythema annulare centrifugum.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subacute cutaneous lupus erythematosus</strong> – Subacute cutaneous lupus erythematosus is a subtype of cutaneous lupus erythematous that can manifest as annular or polycyclic, scaly plaques on sun-exposed skin  (<a class="graphic graphic_picture graphicRef55903" href="/d/graphic/55903.html" rel="external">picture 26</a>). Subacute cutaneous lupus erythematosus can be idiopathic or occur in association with systemic lupus erythematosus or drug exposure. (See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Subacute cutaneous lupus erythematosus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Granuloma annulare</strong> – Granuloma annulare is a benign, inflammatory condition that classically presents with one or more erythematous or violaceous, annular plaques on the extremities  (<a class="graphic graphic_picture graphicRef109887 graphicRef131148 graphicRef61039" href="/d/graphic/109887.html" rel="external">picture 27A-C</a>). Unlike tinea corporis, scale is absent. (See  <a class="medical medical_review" href="/d/html/13705.html" rel="external">"Granuloma annulare: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythema annulare centrifugum</strong> – Erythema annulare centrifugum, an inflammatory skin disorder of unknown etiology, exhibits annular plaques  (<a class="graphic graphic_picture graphicRef80998 graphicRef59741" href="/d/graphic/80998.html" rel="external">picture 28A-B</a>). A trailing rim of scale is often evident in the superficial variant of this disorder. (See  <a class="medical medical_review" href="/d/html/110153.html" rel="external">"Erythema annulare centrifugum"</a>.)</p><p></p><p>Other disorders, such as nummular eczema  (<a class="graphic graphic_picture graphicRef116644 graphicRef96164" href="/d/graphic/116644.html" rel="external">picture 29A-B</a>), psoriasis, pityriasis rosea  (<a class="graphic graphic_picture graphicRef57568 graphicRef98333" href="/d/graphic/57568.html" rel="external">picture 30A-B</a>), and disciform erythrasma  (<a class="graphic graphic_picture graphicRef85723" href="/d/graphic/85723.html" rel="external">picture 31</a>), may also exhibit scaling plaques that resemble tinea corporis. (See  <a class="medical medical_review" href="/d/html/13690.html" rel="external">"Approach to the patient with annular skin lesions"</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The extent of skin involvement with tinea corporis influences the approach to treatment  (<a class="graphic graphic_algorithm graphicRef131608" href="/d/graphic/131608.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited disease</strong> – Tinea corporis usually responds well to topical antifungal drugs, such as azoles, allylamines, <a class="drug drug_general" data-topicid="9177" href="/d/drug information/9177.html" rel="external">butenafine</a>, <a class="drug drug_general" data-topicid="9263" href="/d/drug information/9263.html" rel="external">ciclopirox</a>, <a class="drug drug_general" data-topicid="10005" href="/d/drug information/10005.html" rel="external">tolnaftate</a>, and amorolfine  (<a class="graphic graphic_table graphicRef76148" href="/d/graphic/76148.html" rel="external">table 1</a>) [<a href="#rid18">18,38</a>]. Topical <a class="drug drug_general" data-topicid="9712" href="/d/drug information/9712.html" rel="external">nystatin</a> is <strong>not</strong> effective for dermatophyte infections. Amorolfine is not available in the United States.</p><p></p><p class="bulletIndent1">Topical antifungal treatment is generally administered once or twice per day for one to three weeks  (<a class="graphic graphic_table graphicRef76148" href="/d/graphic/76148.html" rel="external">table 1</a>). The endpoint of treatment is clinical resolution.</p><p></p><p class="bulletIndent1">The topical antifungal agents listed above are all considered effective. Pooled data from randomized trials supports the efficacy of two allylamines, <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> and <a class="drug drug_general" data-topicid="9675" href="/d/drug information/9675.html" rel="external">naftifine</a>, for tinea corporis and tinea cruris [<a href="#rid18">18</a>]. There are also data that suggest similar efficacy of topical allylamines and topical azoles [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extensive or refractory disease</strong> – Oral treatment is an alternative for patients with extensive skin involvement and patients who fail topical therapy. Potential causes of treatment failure should be reviewed. (See <a class="local">'Treatment failure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment options</strong> – <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">Terbinafine</a> and <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> are common treatments. <a class="drug drug_general" data-topicid="8502" href="/d/drug information/8502.html" rel="external">Griseofulvin</a> and <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> can also be effective but may require longer courses of therapy. Small, randomized trials support the efficacy of these oral antifungal therapies [<a href="#rid39">39-43</a>]. Patient comorbidities, risk for drug interactions, and regimen preference influence the selection of an initial oral therapy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Impact of antifungal resistance</strong> – Although historically all four major oral antifungal therapies used for tinea corporis and tinea cruris have been considered effective for tinea corporis and tinea cruris [<a href="#rid43">43</a>], local resistance patterns may impact treatment efficacy, particularly given the increasing prevalence of <em>T. indotineae. </em>Where available, susceptibility testing is helpful for treatment selection after treatment failure. (See <a class="local">'Treatment failure'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a trial performed in 2017 and 2018 in India, 200 adults and children with chronic (≥3 months) or chronically relapsing tinea corporis, tinea cruris, or tinea faciei were randomly assigned to treatment with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (approximately 5 mg/kg per day), <a class="drug drug_general" data-topicid="8502" href="/d/drug information/8502.html" rel="external">griseofulvin</a> microsize (approximately 10 mg/kg per day in two divided doses), <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> (approximately 5 mg/kg per day), or <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> (approximately 7.5 mg/kg per day) [<a href="#rid44">44</a>]. Doses were rounded to the nearest half-tablet or capsule dose, and treatment was given for up to eight weeks. At week 4, all four treatments were similarly <strong>ineffective</strong> for achieving complete clinical cure plus negative KOH microscopy, with cure rates ≤8 percent in all groups. At week 8, itraconazole was more effective than fluconazole, terbinafine, and griseofulvin (cure in 66, 42, 38, and 14 percent of patients, respectively). Fluconazole was also more effective than griseofulvin. (See <a class="local">'Treatment failure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adult dosing</strong> – Reasonable regimens in adults are provided in a table  (<a class="graphic graphic_table graphicRef142691" href="/d/graphic/142691.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent2">Longer courses may be necessary in some cases [<a href="#rid43">43,45</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pediatric dosing</strong> – Children are treated for similar durations as adults. Reasonable pediatric doses are provided in a table  (<a class="graphic graphic_table graphicRef142691" href="/d/graphic/142691.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of newer oral antifungal drugs</strong> – Use of newer antifungal agents, such as <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, and fosravuconazole, for patients with tinea corporis or tinea cruris resistant to standard oral antifungal therapies has been reported [<a href="#rid46">46-49</a>]. These therapies are reserved for infections that cannot be treated with standard therapy. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles"</a>.)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">TINEA CRURIS</span></p><p class="headingAnchor" id="H2696183692"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Tinea cruris (also known as jock itch) is a dermatophyte infection involving the crural fold.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology and risk factors</strong> – The most common cause is <em>T. rubrum</em>. Other frequent causes include <em>E. floccosum</em>, <em>T. mentagrophytes</em>/<em>interdigitale</em> complex, and<em> T. indotineae</em>.</p><p></p><p class="bulletIndent1">Tinea cruris is far more common in males than females. Often, infection results from the spread of the dermatophyte infection from concomitant tinea pedis. Predisposing factors include copious sweating, obesity, diabetes, and immunodeficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Tinea cruris often begins with an erythematous or hyperpigmented patch on the proximal medial thigh. The infection spreads centrifugally, with partial central clearing and a slightly elevated, erythematous or hyperpigmented, sharply demarcated border  (<a class="graphic graphic_picture graphicRef71067 graphicRef129944 graphicRef129802 graphicRef117699 graphicRef76169" href="/d/graphic/71067.html" rel="external">picture 3A-E</a>).</p><p></p><p class="bulletIndent1">Infection may spread to the perineum and perianal areas, into the gluteal cleft, or onto the buttocks. In males, the scrotum is typically spared.</p><p></p><p class="headingAnchor" id="H68628406"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Other common skin disorders that may present with erythematous patches or plaques in the inguinal region include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidal intertrigo</strong> – Candidiasis is suggested by inflamed patches with satellite papules and pustules  (<a class="graphic graphic_picture graphicRef99894" href="/d/graphic/99894.html" rel="external">picture 32</a>). Candidal pseudohyphae, hyphae, and yeast cells are seen on potassium hydroxide (KOH) preparation  (<a class="graphic graphic_picture graphicRef51081 graphicRef64872" href="/d/graphic/51081.html" rel="external">picture 8A-B</a>). In contrast to tinea cruris, scrotal involvement is common in males with candidiasis of the crural folds. (See  <a class="medical medical_review" href="/d/html/115366.html" rel="external">"Intertrigo"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seborrheic dermatitis</strong> – Intertriginous seborrheic dermatitis may present as moist, erythematous, or hyperpigmented patches in the genitocrural area  (<a class="graphic graphic_picture graphicRef103986" href="/d/graphic/103986.html" rel="external">picture 33</a>). Patients may also have findings of seborrheic dermatitis in other body areas. (See  <a class="medical medical_review" href="/d/html/13669.html" rel="external">"Seborrheic dermatitis in adolescents and adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inverse psoriasis</strong> – Inverse psoriasis typically presents as smooth, shiny plaques with absent or minimal scale in intertriginous areas  (<a class="graphic graphic_picture graphicRef103985 graphicRef99439" href="/d/graphic/103985.html" rel="external">picture 34A-B</a>). Patients may or may not have psoriasis in other body areas. (See  <a class="medical medical_review" href="/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Inverse (intertriginous) psoriasis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythrasma</strong> – Erythrasma is a superficial bacterial infection of the skin caused by <em>Corynebacterium minutissimum</em>. Intertriginous involvement may present as erythematous to brown patches or thin plaques  (<a class="graphic graphic_picture graphicRef99904 graphicRef99905" href="/d/graphic/99904.html" rel="external">picture 35A-B</a>). The detection of coral red fluorescence during examination with a Wood's lamp can confirm the diagnosis  (<a class="graphic graphic_picture graphicRef62143" href="/d/graphic/62143.html" rel="external">picture 36</a>). (See  <a class="medical medical_review" href="/d/html/4031.html" rel="external">"Erythrasma"</a>.)</p><p></p><p>A KOH preparation positive for hyphae rules out nonfungal disorders. (See <a class="local">'Diagnosis'</a> above.)</p><p class="headingAnchor" id="H30"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Treatment is similar to treatment of tinea corporis  (<a class="graphic graphic_algorithm graphicRef131608" href="/d/graphic/131608.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy</strong> – Topical therapy with antifungal agents, such as azoles, allylamines, <a class="drug drug_general" data-topicid="9177" href="/d/drug information/9177.html" rel="external">butenafine</a>, <a class="drug drug_general" data-topicid="9263" href="/d/drug information/9263.html" rel="external">ciclopirox</a>, <a class="drug drug_general" data-topicid="10005" href="/d/drug information/10005.html" rel="external">tolnaftate</a>, or amorolfine, is effective  (<a class="graphic graphic_table graphicRef76148" href="/d/graphic/76148.html" rel="external">table 1</a>) [<a href="#rid18">18,38</a>]. <a class="drug drug_general" data-topicid="9712" href="/d/drug information/9712.html" rel="external">Nystatin</a> is <strong>not </strong>effective for dermatophyte infections. (See <a class="local">'Tinea corporis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extensive or refractory to topical therapy</strong> – Tinea cruris that is extensive or fails to resolve with topical therapy can be treated with the oral antifungal regimens used for tinea corporis. (See <a class="local">'Tinea corporis'</a> above.)</p><p></p><p class="bulletIndent1">Potential causes for treatment failure should be reviewed. (See <a class="local">'Treatment failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Recurrence of tinea cruris is common. Concomitant tinea pedis should be treated to reduce risk for recurrence. Treatment of onychomycosis may also reduce recurrences. Other interventions that may be helpful include daily use of desiccant powders or drying lotions in the inguinal area and avoidance of tight-fitting clothing and noncotton underwear.</p><p></p><p class="headingAnchor" id="H68628955"><span class="h1">OTHER CLINICAL VARIANTS</span><span class="headingEndMark"> — </span>Various other terms are used to describe additional clinical subtypes of dermatophyte infection.</p><p class="headingAnchor" id="H1698047091"><span class="h2">Onychomycosis</span><span class="headingEndMark"> — </span>Dermatophyte infection is a common cause of onychomycosis (fungal infection of the nail). Clinical manifestations include nail discoloration, subungual hyperkeratosis, and other forms of nail dystrophy  (<a class="graphic graphic_picture graphicRef120659" href="/d/graphic/120659.html" rel="external">picture 5</a>). Onychomycosis is reviewed separately. (See  <a class="medical medical_review" href="/d/html/4034.html" rel="external">"Onychomycosis: Epidemiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/105222.html" rel="external">"Onychomycosis: Management"</a>.)</p><p class="headingAnchor" id="H68628972"><span class="h2">Tinea faciei</span><span class="headingEndMark"> — </span>Tinea faciei is a dermatophyte infection of facial skin devoid of terminal hairs. The eruption may begin as small, scaly papules that evolve to form an annular plaque  (<a class="graphic graphic_picture graphicRef78234" href="/d/graphic/78234.html" rel="external">picture 37</a>) [<a href="#rid28">28</a>]. Tinea faciei is managed similarly to tinea corporis. (See <a class="local">'Tinea corporis'</a> above.)</p><p class="headingAnchor" id="H68628978"><span class="h2">Tinea manuum</span><span class="headingEndMark"> — </span>Tinea manuum is a dermatophyte infection of the hand. Patients present with a hyperkeratotic eruption on the palm or annular plaques similar to tinea corporis on the dorsal hand.</p><p>Tinea manuum commonly occurs in association with tinea pedis and is often unilateral  (<a class="graphic graphic_picture graphicRef129202 graphicRef57816" href="/d/graphic/129202.html" rel="external">picture 12A-B</a>). This clinical presentation is often referred to as "two feet-one hand syndrome." The approach to treatment is similar to tinea pedis. (See <a class="local">'Tinea pedis'</a> above.)</p><p class="headingAnchor" id="H68628854"><span class="h2">Tinea capitis</span><span class="headingEndMark"> — </span>Tinea capitis, a dermatophyte infection of scalp hair, usually occurs in small children  (<a class="graphic graphic_picture graphicRef101858 graphicRef86686" href="/d/graphic/101858.html" rel="external">picture 4A-B</a>). Oral antifungal therapy is the treatment of choice. Tinea capitis is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/99983.html" rel="external">"Tinea capitis"</a>.)</p><p class="headingAnchor" id="H68628872"><span class="h2">Tinea barbae</span><span class="headingEndMark"> — </span>Tinea barbae is a dermatophyte infection involving beard hair in adolescent and adult males  (<a class="graphic graphic_picture graphicRef86999 graphicRef87000" href="/d/graphic/86999.html" rel="external">picture 38A-B</a>). Oral antifungal therapy is necessary. Tinea barbae is reviewed separately. (See  <a class="medical medical_review" href="/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Dermatophytic folliculitis'</a> and  <a class="medical medical_review" href="/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Management'</a>.) </p><p class="headingAnchor" id="H4290218187"><span class="h2">Majocchi's granuloma</span><span class="headingEndMark"> — </span>Majocchi's granuloma is an uncommon subtype of dermatophyte infection in which the dermatophyte invades the deep follicle and dermis. The clinical findings are typically characterized by a localized area with erythematous or hyperpigmented, perifollicular papules or small nodules  (<a class="graphic graphic_picture graphicRef103536 graphicRef129800 graphicRef103535" href="/d/graphic/103536.html" rel="external">picture 6A-C</a>). Pustules may also be present. </p><p>Treatment consists of oral antifungal therapy. Majocchi's granuloma is reviewed separately. (See  <a class="medical medical_review" href="/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Dermatophytic folliculitis'</a> and  <a class="medical medical_review" href="/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Management'</a>.)</p><p class="headingAnchor" id="H328395034"><span class="h2">Tinea imbricata</span><span class="headingEndMark"> — </span>Tinea imbricata (also known as Tokelau ringworm) is a variant of tinea corporis caused by <em>Trichophyton concentricum</em>. The disorder primarily occurs in the South Pacific Islands, South Asia, and South America. </p><p>Tinea imbricata is characterized by concentric, annular, scaly, erythematous plaques  (<a class="graphic graphic_picture graphicRef104034 graphicRef104036" href="/d/graphic/104034.html" rel="external">picture 39A-B</a>). A potassium hydroxide (KOH) preparation demonstrates hyphae, and fungal culture confirms <em>T. concentricum</em> infection. </p><p>The most effective treatments may be oral <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> and <a class="drug drug_general" data-topicid="8502" href="/d/drug information/8502.html" rel="external">griseofulvin</a> [<a href="#rid50">50</a>]. Systemic therapy is often combined with a topical keratolytic agent.</p><p class="headingAnchor" id="H3519874552"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112069.html" rel="external">"Society guideline links: Dermatophyte infections"</a>.)</p><p class="headingAnchor" id="H18300298"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15478.html" rel="external">"Patient education: Ringworm, athlete's foot, and jock itch (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16898.html" rel="external">"Patient education: Fungal nail infections (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/7639.html" rel="external">"Patient education: Ringworm (including athlete's foot and jock itch) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H35"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Superficial fungal infections are most commonly caused by dermatophytes in the <em>Trichophyton</em>, <em>Epidermophyton</em>, and <em>Microsporum</em> genera. These organisms metabolize keratin and cause a range of pathologic clinical presentations, including tinea pedis  (<a class="graphic graphic_picture graphicRef76067 graphicRef103981 graphicRef82787" href="/d/graphic/76067.html" rel="external">picture 1A-C</a>), tinea corporis  (<a class="graphic graphic_picture graphicRef129803 graphicRef103984 graphicRef99892 graphicRef75928" href="/d/graphic/129803.html" rel="external">picture 2A-D</a>), tinea cruris  (<a class="graphic graphic_picture graphicRef71067 graphicRef129944 graphicRef129802 graphicRef117699 graphicRef76169" href="/d/graphic/71067.html" rel="external">picture 3A-E</a>), tinea capitis, and onychomycosis. (See <a class="local">'Microbiology'</a> above and <a class="local">'Tinea pedis'</a> above and <a class="local">'Tinea corporis'</a> above and <a class="local">'Tinea cruris'</a> above and <a class="local">'Other clinical variants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A diagnosis of a cutaneous dermatophyte infection may be strongly suspected based upon the clinical findings. A potassium hydroxide (KOH) preparation can be used to confirm the diagnosis  (<a class="graphic graphic_picture graphicRef100246" href="/d/graphic/100246.html" rel="external">picture 7A</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment principles</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General approach</strong> – Treatment of tinea pedis, tinea corporis, and tinea cruris is indicated to alleviate symptoms (eg, pruritus), reduce risk for secondary bacterial infection, and limit spread of the infection to other body sites or other individuals.</p><p></p><p class="bulletIndent2">Most dermatophyte infections can be managed with topical antifungal treatments. Oral therapy is typically reserved for refractory or extensive infections because of the broader adverse effect profile compared with topical therapy. (See <a class="local">'Treatment options'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inefficacy of </strong><strong>nystatin</strong> – <a class="drug drug_general" data-topicid="9712" href="/d/drug information/9712.html" rel="external">Nystatin</a> is<strong> not</strong> effective for dermatophyte infections. (See <a class="local">'Nystatin ineffective'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adjunctive corticosteroids</strong> – Adjunctive topical corticosteroid therapy is <strong>not</strong> indicated for most patients. However, for patients with highly inflammatory lesions who require relief from severe pruritus, we suggest the addition of a <strong>low-potency</strong> topical corticosteroid (group 6 or 7  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 2</a>)) to antifungal therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We avoid use of products containing medium-potency or high-potency topical corticosteroids (eg, <a class="drug drug_general" data-topicid="8655" href="/d/drug information/8655.html" rel="external">betamethasone-clotrimazole</a>).</p><p></p><p class="bulletIndent2">Topical corticosteroid therapy is not necessary for cure and introduces risk for topical corticosteroid-induced skin atrophy. Overuse of topical corticosteroids is also postulated to contribute to the emergence of antifungal resistance. (See <a class="local">'Adjunctive corticosteroid therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment failure</strong> – When topical therapy fails to resolve a dermatophyte infection, potential reasons for treatment failure should be reviewed. Common reasons for treatment failure include inadequate administration of treatment and an incorrect diagnosis  (<a class="graphic graphic_algorithm graphicRef131608" href="/d/graphic/131608.html" rel="external">algorithm 1</a>). The possibilities of reinfection and antifungal resistance should also be reviewed. (See <a class="local">'Treatment failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of tinea pedis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy</strong> – For patients with tinea pedis, we suggest initial treatment with a topical antifungal drug with antidermatophyte activity rather than oral antifungal therapy  (<a class="graphic graphic_algorithm graphicRef131608" href="/d/graphic/131608.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Examples of effective topical antifungal agents are azoles, allylamines, <a class="drug drug_general" data-topicid="9263" href="/d/drug information/9263.html" rel="external">ciclopirox</a>, <a class="drug drug_general" data-topicid="9177" href="/d/drug information/9177.html" rel="external">butenafine</a>, and <a class="drug drug_general" data-topicid="10005" href="/d/drug information/10005.html" rel="external">tolnaftate</a>  (<a class="graphic graphic_table graphicRef76148" href="/d/graphic/76148.html" rel="external">table 1</a>). Topical antifungal treatment is generally applied once or twice daily and continued for four weeks. Topical <a class="drug drug_general" data-topicid="9712" href="/d/drug information/9712.html" rel="external">nystatin</a> is<strong> not</strong> effective. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory infections</strong> – For patients with tinea pedis refractory to topical therapy, we suggest treatment with oral <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a>, oral <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, or oral <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> rather than oral <a class="drug drug_general" data-topicid="8502" href="/d/drug information/8502.html" rel="external">griseofulvin</a>  (<a class="graphic graphic_table graphicRef142692" href="/d/graphic/142692.html" rel="external">table 3</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Griseofulvin is a reasonable alternative but may require a longer duration of daily treatment compared with terbinafine and itraconazole. Selection among these therapies is based upon consideration of patient comorbidities, risk for drug interactions, and regimen preference. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of tinea corporis or tinea cruris</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy</strong> – For most patients with tinea corporis or tinea cruris, we suggest initial treatment with a topical antifungal drug with antidermatophyte activity rather than oral antifungal therapy  (<a class="graphic graphic_algorithm graphicRef131608" href="/d/graphic/131608.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Examples of effective topical antifungal agents are azoles, allylamines, <a class="drug drug_general" data-topicid="9263" href="/d/drug information/9263.html" rel="external">ciclopirox</a>, <a class="drug drug_general" data-topicid="9177" href="/d/drug information/9177.html" rel="external">butenafine</a>, and <a class="drug drug_general" data-topicid="10005" href="/d/drug information/10005.html" rel="external">tolnaftate</a>  (<a class="graphic graphic_table graphicRef76148" href="/d/graphic/76148.html" rel="external">table 1</a>). Topical antifungal treatment is generally administered once or twice per day for one to three weeks. Topical <a class="drug drug_general" data-topicid="9712" href="/d/drug information/9712.html" rel="external">nystatin</a> is<strong> not</strong> effective. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extensive infections or refractory infections</strong> – For patients with extensive tinea corporis or tinea cruris or patients with infections refractory to topical therapy, we suggest oral antifungal therapy rather than topical antifungal therapy  (<a class="graphic graphic_algorithm graphicRef131608" href="/d/graphic/131608.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Options include oral <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a>, <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, and <a class="drug drug_general" data-topicid="8502" href="/d/drug information/8502.html" rel="external">griseofulvin</a>  (<a class="graphic graphic_table graphicRef142691" href="/d/graphic/142691.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent2">In the absence of known resistance to specific oral antifungal therapies, we treat most patients with <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a>, <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, or <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> because of the longer course of daily treatment associated with <a class="drug drug_general" data-topicid="8502" href="/d/drug information/8502.html" rel="external">griseofulvin</a> compared with terbinafine and itraconazole. Selection among these therapies is based upon consideration of patient comorbidities, risk for drug interactions, and regimen preference.</p><p></p><p class="bulletIndent2">In the event of oral antifungal treatment failure, susceptibility testing (where available) is helpful for selecting subsequent therapy. (See <a class="local">'Treatment'</a> above and <a class="local">'Treatment failure'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses 2008; 51 Suppl 4:2.</a></li><li><a class="nounderline abstract_t">Seebacher C, Bouchara JP, Mignon B. Updates on the epidemiology of dermatophyte infections. Mycopathologia 2008; 166:335.</a></li><li><a class="nounderline abstract_t">Ameen M. Epidemiology of superficial fungal infections. Clin Dermatol 2010; 28:197.</a></li><li><a class="nounderline abstract_t">Levitt JO, Levitt BH, Akhavan A, Yanofsky H. The sensitivity and specificity of potassium hydroxide smear and fungal culture relative to clinical assessment in the evaluation of tinea pedis: a pooled analysis. Dermatol Res Pract 2010; 2010:764843.</a></li><li><a class="nounderline abstract_t">Solomon M, Greenbaum H, Shemer A, et al. Toe Web Infection: Epidemiology and Risk Factors in a Large Cohort Study. Dermatology 2021; 237:902.</a></li><li><a class="nounderline abstract_t">Meena S, Gupta LK, Khare AK, et al. Topical Corticosteroids Abuse: A Clinical Study of Cutaneous Adverse Effects. Indian J Dermatol 2017; 62:675.</a></li><li><a class="nounderline abstract_t">Verma SB. A Closer Look at the Term "Tinea Incognito:" A Factual as Well as Grammatical Inaccuracy. Indian J Dermatol 2017; 62:219.</a></li><li><a class="nounderline abstract_t">Holubar K, Male O. Tinea incognita vs. tinea incognito. Acta Dermatovenerol Croat 2002; 10:39.</a></li><li><a class="nounderline abstract_t">Ilkit M, Durdu M, Karakaş M. Majocchi's granuloma: a symptom complex caused by fungal pathogens. Med Mycol 2012; 50:449.</a></li><li><a class="nounderline abstract_t">Smith KJ, Neafie RC, Skelton HG 3rd, et al. Majocchi's granuloma. J Cutan Pathol 1991; 18:28.</a></li><li><a class="nounderline abstract_t">Tse KC, Yeung CK, Tang S, et al. Majocchi's granuloma and posttransplant lymphoproliferative disease in a renal transplant recipient. Am J Kidney Dis 2001; 38:E38.</a></li><li><a class="nounderline abstract_t">Kim ST, Baek JW, Kim TK, et al. Majocchi's granuloma in a woman with iatrogenic Cushing's syndrome. J Dermatol 2008; 35:789.</a></li><li><a class="nounderline abstract_t">Akiba H, Motoki Y, Satoh M, et al. Recalcitrant trichophytic granuloma associated with NK-cell deficiency in a SLE patient treated with corticosteroid. Eur J Dermatol 2001; 11:58.</a></li><li><a class="nounderline abstract_t">Cheng N, Rucker Wright D, Cohen BA. Dermatophytid in tinea capitis: rarely reported common phenomenon with clinical implications. Pediatrics 2011; 128:e453.</a></li><li><a class="nounderline abstract_t">Romano C, Rubegni P, Ghilardi A, Fimiani M. A case of bullous tinea pedis with dermatophytid reaction caused by Trichophyton violaceum. Mycoses 2006; 49:249.</a></li><li><a class="nounderline abstract_t">Al Aboud K, Al Hawsawi K, Alfadley A. Tinea incognito on the hand causing a facial dermatophytid reaction. Acta Derm Venereol 2003; 83:59.</a></li><li><a class="nounderline abstract_t">Veien NK, Hattel T, Laurberg G. Plantar Trichophyton rubrum infections may cause dermatophytids on the hands. Acta Derm Venereol 1994; 74:403.</a></li><li><a class="nounderline abstract_t">El-Gohary M, van Zuuren EJ, Fedorowicz Z, et al. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev 2014; :CD009992.</a></li><li><a class="nounderline abstract_t">Alston SJ, Cohen BA, Braun M. Persistent and recurrent tinea corporis in children treated with combination antifungal/ corticosteroid agents. Pediatrics 2003; 111:201.</a></li><li><a class="nounderline abstract_t">Greenberg HL, Shwayder TA, Bieszk N, Fivenson DP. Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections. Pediatr Dermatol 2002; 19:78.</a></li><li><a class="nounderline abstract_t">Rosen T, Elewski BE. Failure of clotrimazole-betamethasone dipropionate cream in treatment of Microsporum canis infections. J Am Acad Dermatol 1995; 32:1050.</a></li><li><a class="nounderline abstract_t">Nahm WK, Orengo I, Rosen T. The antifungal agent butenafine manifests anti-inflammatory activity in vivo. J Am Acad Dermatol 1999; 41:203.</a></li><li><a class="nounderline abstract_t">Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997; 36:788.</a></li><li><a class="nounderline abstract_t">Gupta AK, Renaud HJ, Quinlan EM, et al. The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses. Am J Clin Dermatol 2021; 22:149.</a></li><li><a class="nounderline abstract_t">Gupta AK, Venkataraman M, Hall DC, et al. The emergence of Trichophyton indotineae: Implications for clinical practice. Int J Dermatol 2023; 62:857.</a></li><li><a class="nounderline abstract_t">Caplan AS, Chaturvedi S, Zhu Y, et al. Notes from the Field: First Reported U.S. Cases of Tinea Caused by Trichophyton indotineae - New York City, December 2021-March 2023. MMWR Morb Mortal Wkly Rep 2023; 72:536.</a></li><li><a class="nounderline abstract_t">Jabet A, Normand AC, Brun S, et al. Trichophyton indotineae, from epidemiology to therapeutic. J Mycol Med 2023; 33:101383.</a></li><li><a class="nounderline abstract_t">Hawkins DM, Smidt AC. Superficial fungal infections in children. Pediatr Clin North Am 2014; 61:443.</a></li><li><a class="nounderline abstract_t">Sasagawa Y. Internal environment of footwear is a risk factor for tinea pedis. J Dermatol 2019; 46:940.</a></li><li><a class="nounderline abstract_t">Al-Mahmood A, Al-Sharifi E. Epidemiological Characteristics and Risk Factors of Tinea Pedis Disease Among Adults Attending Tikrit Teaching Hospital/ Iraq. Infect Disord Drug Targets 2021; 21:384.</a></li><li><a class="nounderline abstract_t">Oz Y, Qoraan I, Oz A, Balta I. Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey. Int J Dermatol 2017; 56:68.</a></li><li><a class="nounderline abstract_t">Korting HC, Tietz HJ, Bräutigam M, et al. One week terbinafine 1% cream (Lamisil) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. LAS-INT-06 Study Group. Med Mycol 2001; 39:335.</a></li><li><a class="nounderline abstract_t">Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007; :CD001434.</a></li><li><a class="nounderline abstract_t">Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008; 166:353.</a></li><li><a class="nounderline abstract_t">Bell-Syer SE, Khan SM, Torgerson DJ. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev 2012; 10:CD003584.</a></li><li><a class="nounderline abstract_t">Echuri H, Sivesind TE, Dellavalle RP. From the Cochrane library: Oral treatments for fungal infections of the skin of the foot. J Am Acad Dermatol 2022; 87:e183.</a></li><li><a class="nounderline abstract_t">Adams BB. Tinea corporis gladiatorum. J Am Acad Dermatol 2002; 47:286.</a></li><li><a class="nounderline abstract_t">van Zuuren EJ, Fedorowicz Z, El-Gohary M. Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. Br J Dermatol 2015; 172:616.</a></li><li><a class="nounderline abstract_t">Bourlond A, Lachapelle JM, Aussems J, et al. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol 1989; 28:410.</a></li><li><a class="nounderline abstract_t">Cole GW, Stricklin G. A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis. Arch Dermatol 1989; 125:1537.</a></li><li><a class="nounderline abstract_t">Panagiotidou D, Kousidou T, Chaidemenos G, et al. A comparison of itraconazole and griseofulvin in the treatment of tinea corporis and tinea cruris: a double-blind study. J Int Med Res 1992; 20:392.</a></li><li><a class="nounderline abstract_t">Faergemann J, Mörk NJ, Haglund A, Odegård T. A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. Br J Dermatol 1997; 136:575.</a></li><li><a class="nounderline abstract_t">del Palacio Hernandez A, López Gómez S, González Lastra F, et al. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris. Clin Exp Dermatol 1990; 15:210.</a></li><li><a class="nounderline abstract_t">Singh S, Chandra U, Anchan VN, et al. Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial. Br J Dermatol 2020; 183:840.</a></li><li><a class="nounderline abstract_t">Khurana A, Agarwal A, Agrawal D, et al. Effect of Different Itraconazole Dosing Regimens on Cure Rates, Treatment Duration, Safety, and Relapse Rates in Adult Patients With Tinea Corporis/Cruris: A Randomized Clinical Trial. JAMA Dermatol 2022; 158:1269.</a></li><li><a class="nounderline abstract_t">Chen E, Ghannoum M, Elewski BE. Treatment-resistant tinea corporis, a potential public health issue. Br J Dermatol 2021; 184:164.</a></li><li><a class="nounderline abstract_t">Khurana A, Agarwal A, Agrawal D, et al. Multidrug resistant tinea corporis/cruris: Response to voriconazole. J Mycol Med 2022; 32:101306.</a></li><li><a class="nounderline abstract_t">Kitauchi Y, Kumagai Y, Inoue-Masuda Y, et al. Tinea corporis caused by terbinafine-resistant Trichophyton rubrum successfully treated with fosravuconazole. J Dermatol 2021; 48:e329.</a></li><li><a class="nounderline abstract_t">Gupta AK, Talukder M, Venkataraman M. Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole. Int J Dermatol 2022; 61:1431.</a></li><li><a class="nounderline abstract_t">Bonifaz A, Vázquez-González D. Tinea imbricata in the Americas. Curr Opin Infect Dis 2011; 24:106.</a></li></ol></div><div id="topicVersionRevision">Topic 4030 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18783559" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiological trends in skin mycoses worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18478365" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Updates on the epidemiology of dermatophyte infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20347663" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology of superficial fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20672004" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The sensitivity and specificity of potassium hydroxide smear and fungal culture relative to clinical assessment in the evaluation of tinea pedis: a pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33105147" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Toe Web Infection: Epidemiology and Risk Factors in a Large Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29263550" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Topical Corticosteroids Abuse: A Clinical Study of Cutaneous Adverse Effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28400650" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A Closer Look at the Term "Tinea Incognito:" A Factual as Well as Grammatical Inaccuracy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12185992" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tinea incognita vs. tinea incognito.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22435879" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Majocchi's granuloma: a symptom complex caused by fungal pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2022763" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Majocchi's granuloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11728998" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Majocchi's granuloma and posttransplant lymphoproliferative disease in a renal transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19239561" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Majocchi's granuloma in a woman with iatrogenic Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174142" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Recalcitrant trichophytic granuloma associated with NK-cell deficiency in a SLE patient treated with corticosteroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21727102" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Dermatophytid in tinea capitis: rarely reported common phenomenon with clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16681820" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A case of bullous tinea pedis with dermatophytid reaction caused by Trichophyton violaceum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12636029" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Tinea incognito on the hand causing a facial dermatophytid reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7817685" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Plantar Trichophyton rubrum infections may cause dermatophytids on the hands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25090020" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Topical antifungal treatments for tinea cruris and tinea corporis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12509578" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Persistent and recurrent tinea corporis in children treated with combination antifungal/ corticosteroid agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11860579" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751452" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Failure of clotrimazole-betamethasone dipropionate cream in treatment of Microsporum canis infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10426889" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The antifungal agent butenafine manifests anti-inflammatory activity in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9372359" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Anti-inflammatory activity of antifungal preparations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33354740" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35867962" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The emergence of Trichophyton indotineae: Implications for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37167192" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Notes from the Field: First Reported U.S. Cases of Tinea Caused by Trichophyton indotineae - New York City, December 2021-March 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37031652" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Trichophyton indotineae, from epidemiology to therapeutic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24636655" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Superficial fungal infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31436337" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Internal environment of footwear is a risk factor for tinea pedis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32634085" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Epidemiological Characteristics and Risk Factors of Tinea Pedis Disease Among Adults Attending Tikrit Teaching Hospital/ Iraq.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27667305" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11556763" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : One week terbinafine 1% cream (Lamisil) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. LAS-INT-06 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636672" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Topical treatments for fungal infections of the skin and nails of the foot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18478357" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Update in antifungal therapy of dermatophytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076898" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Oral treatments for fungal infections of the skin of the foot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35810839" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : From the Cochrane library: Oral treatments for fungal infections of the skin of the foot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12140477" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tinea corporis gladiatorum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25294700" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2548967" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2684023" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1333423" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A comparison of itraconazole and griseofulvin in the treatment of tinea corporis and tinea cruris: a double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9155961" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194715" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32538466" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36103158" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of Different Itraconazole Dosing Regimens on Cure Rates, Treatment Duration, Safety, and Relapse Rates in Adult Patients With Tinea Corporis/Cruris: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33428216" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Treatment-resistant tinea corporis, a potential public health issue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35785725" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Multidrug resistant tinea corporis/cruris: Response to voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33860550" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Tinea corporis caused by terbinafine-resistant Trichophyton rubrum successfully treated with fosravuconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34882787" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21169831" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Tinea imbricata in the Americas.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
